FDA Launches Program To Share Approval Reviews With Foreign Regulators, Expanding To Novel Drugs In 2027
By Elizabeth Urbanek, Executive Editor

The FDA has launched a program that lets drug and biologic sponsors share minimally redacted copies of the agency's approval reviews with regulators in other countries. The program starts narrow, but the FDA plans to extend it to all novel drugs and biologics in January 2027, which could affect how quickly products reach markets outside the U.S.
Announced Nov. 17, the Global Reliance Disclosure Program (GRDP) gives applicants FDA approval packages that include the agency's scientific and regulatory assessments. Applicants can then submit those packages to foreign regulators to support marketing applications. The FDA said the program began Oct. 30.
To take part, an applicant must request the package within 10 calendar days of approval and confirm it will go to a foreign regulatory authority with a marketing application. Requests for any other purpose fall under the Freedom of Information Act instead. The FDA said it will include details in approval letters and intends to provide packages on an expedited basis.
For now, the program covers tentative approvals under the President's Emergency Plan for AIDS Relief (PEPFAR), excluding tentatively approved ANDA products. The FDA cited a tentative approval for lenacapavir, an HIV prevention and treatment drug, as an example. In January 2027, the agency intends to expand the program to all new molecular entity NDAs and to biologics license applications (BLAs) filed under Section 351(a) of the Public Health Service Act. It also plans to open a pathway in early 2027 for products the FDA has already approved.
Foreign regulators can use the FDA's review instead of repeating it, while keeping authority over their own decisions. The FDA said the goal is to narrow the gap between U.S. approval and patient access, particularly in lower-resource settings.
The announcement does not name which regulators have agreed to use the packages or estimate how much time reliance could save. It also does not specifically address clinical trial, inspection, or manufacturing information.
What This Means For Clinical Supply
The program targets marketing approvals, not clinical trials. But approval timing outside the U.S. drives several clinical supply decisions, especially how long sponsors keep shipping investigational medicinal products (IMPs) to countries after a product is approved at home.
Open-label extensions and continued-access programs often run until a product is approved and available in a participant's country. If reliance shortens approval timelines in some markets, sponsors may be able to move participants to commercial product sooner. That could shorten continued-access supply, reduce country-specific labeling runs, and limit how much IMP has to be imported, stored, reconciled, and destroyed.
The constraint is timing, and some of it sits outside clinical supply. The 10-day request window means the decision to seek a package has to be made at approval, typically by regulatory affairs. Whether a country can rely on the FDA's review may also depend on how filings are sequenced. Clinical supply teams may not see either decision unless they ask.
There is also a tradeoff. Planning around faster approvals could save cost and shelf life, but each foreign regulator still makes its own decision. Cutting continued-access supply before an approval is in hand risks leaving participants without drug. Regulatory strategy, country operations, clinical, and commercial supply would need to work from one country-by-country timeline.
Before relying on the program, sponsors would need to confirm which regulators in their trial countries accept the packages, how long those reviews take in practice, and whether a request was filed in time. The announcement provides no evidence yet on time saved or on uptake by specific agencies.
For sponsors with novel products approaching U.S. approval after January 2027, the operational question is whether supply plans for countries outside the U.S. should change now or only after reliance shows up in actual approval dates.
The Supply Question
Should supply plans assume faster approvals abroad now, or wait until other regulators actually rely on FDA reviews?
Related Clinical Supply Leader Editorials:
- The Reliance Trap: When Regulatory Strategy Becomes A Clinical Supply Problem
- Why Shelf Life Should Shape Global Country Activation
- Policy Is Redefining Clinical Trials. Clinical Supply Must Respond.
About The Editor:
Elizabeth Urbanek is the Executive Editor for Clinical Supply Leader, where she works with clinical trial supply and logistics professionals across pharma and biotech to bring real-world perspectives, operational challenges, trends, scientific insights and regulatory strategy to the field.
Before joining life sciences media, Elizabeth spent more than 15 years in broadcast, digital and live-event storytelling, helping highly technical teams communicate complex ideas with clarity and impact. She brings that same approach to clinical supply, creating editorial space for experts to share what is happening across clinical trial operations.
Elizabeth is passionate about connecting people and ideas, identifying emerging themes and showcasing work that can move the clinical supply field forward.